NCT07192471View on ClinicalTrials.gov

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

January 23, 2026

Primary Completion Date

March 31, 2029

Study Completion Date

September 30, 2030

Conditions

T-cell NHL (PTCL or CTCL)

Interventions

DRUG

KK2223

Intravenous infusion

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.

All Listed Sponsors

lead

Kyowa Kirin, Inc.

INDUSTRY